Eris Lifesciences Q2 FY26 results: PAT up 39.5% YoY to Rs 134.47 Cr

Profit growth above 25%EBITDA margin expansionResults restatedResults View source PDF Explain this filing

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.5%Reaction day

₹1577.00

prior close

₹1587.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%-2.1% vs market

Pharmaceuticals peers, median of 157sector-0.0%-2.5% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Smallcap 250 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-0.8

15m

-1.7

30m

-2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.5-0.4-2.1-0.0-2.5

Next day

-1.7-0.2-1.5-0.4-1.3

-0.8+0.5-1.2-0.3-0.4

-0.6-0.6-0.0-1.1+0.5

+2.1-1.0+3.1-1.4+3.5

+5.9-1.1+7.0-1.6+7.5

+4.8-2.9+7.8-3.3+8.2

15d

-1.4-3.1+1.7-3.4+2.0

+0.9-3.9+4.8-4.3+5.2

-6.6-5.3-1.3-6.9+0.3

-10.8-6.6-4.2-8.5-2.3

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Eris Lifesciences reported Q2 FY26 consolidated revenue of Rs 792.41 Cr, up 6.9% YoY. Net profit jumped 39.5% to Rs 134.47 Cr. H1 FY26 revenue rose 7.2% to Rs 1,565.41 Cr with PAT up 39.6% at Rs 259.57 Cr. Operating margin expanded to 27.52% from 24.96%. Board approved reappointment of Whole Time Director and an Independent Director for 5 year terms. Walker Chandiok and Co LLP is now the auditor. Prior period figures were restated due to completion of acquisition purchase price allocation.

Likely market impact

Strong earnings beat with sharp margin expansion and PAT growth above 25%; prior period numbers restated due to acquisition accounting.